OptiBiotix Health
plc
("OptiBiotix" or the "Company")
Issue of Options and Related
Party Transaction
OptiBiotix Health plc (AIM: OPTI), a life sciences
business developing compounds to tackle obesity, high cholesterol,
diabetes and skincare, announces that, the Company has issued 6,099,135 options
over new ordinary shares with an exercise price of 16 pence per
share ("New Options") to Stephen O'Hara, CEO of the Company. The
New Options expire on 17 December 2034 and vest on the first
anniversary of the options being granted being 17 December
2025.
The issue of the New Options follows
the expiration of 6,099,135 options over new ordinary shares with
an exercise price of 8 pence per share, granted to Stephen O'Hara,
which expired in September 2024.
Related Party Transaction
The issuance of the New Options to
Stephen O'Hara ("Transaction") is a related party transaction
pursuant to Rule 13 of the AIM Rules.
The directors of the Company
independent of the Transaction, having consulted with the Company's
nominated adviser, Cairn Financial Advisers LLP, consider the terms
of the Transaction to be fair and reasonable insofar as the
Company's shareholders are concerned.
This announcement contains
information which, prior to its disclosure, was considered inside
information for the purposes of the UK Market Abuse Regulation and
the Directors of the Company are responsible for the release of
this announcement.
For
further information, please contact:
|
OptiBiotix Health plc
|
www.optibiotix.com
|
|
Neil Davidson, Chairman
|
Contact via Walbrook
below
|
|
Stephen O'Hara, Chief
Executive
|
|
|
|
|
|
Cairn Financial Advisers LLP (NOMAD)
|
Tel: 020
7213 0880
|
|
Liam Murray / Jo Turner / Ludovico
Lazzaretti
|
|
|
|
|
|
Peterhouse Capital Limited (Joint Broker)
|
Tel: 020
7220 9797
|
|
Duncan Vasey/ Lucy
Williams
|
|
|
Walbrook PR Ltd
|
Mob: 07876
741 001
|
|
Anna Dunphy
|
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI),
which was formed in March 2012, brings science to the development
of compounds which modify the human microbiome - the collective
genome of the microbes in the body - in order to prevent and manage
human disease and promote wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its
own range of consumer supplements and health products. The
Company's current areas of focus include obesity, cardiovascular
health, and diabetes.
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a.
|
Name
|
Stephen O'Hara
|
|
2
|
Reason for notification
|
|
|
a.
|
Position/Status
|
Director
|
|
b.
|
Initial notification/
Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
OptiBiotix Health Plc
|
|
b.
|
LEI
|
213800UKYQFT941QHS14
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Options over new ordinary shares of
2p each
ISIN: GB00BP0RTP38
|
|
b.
|
Nature of the transaction
|
Issue of options pursuant to the New
Options
|
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s) per share
|
Volume(s)
|
|
|
16p
|
6,099,135
|
|
|
|
|
d.
|
Aggregated information
- Volume
- Price
|
|
|
e.
|
Date of the transaction
|
17 December 2024
|
|
f.
|
Place of the transaction
|
London
|